US CDC Vaccine Advisers Delay Vote on Restricting Infant Hepatitis B Vaccination Amid Tense Meeting
A contentious meeting between vaccine advisers for the US Centers for Disease Control and Prevention (CDC) has resulted in a delay to a vote on restricting hepatitis B vaccination for infants. The meeting, which took place earlier this week, turned confrontational at times before one member introduced a motion to delay the vote.
The decision comes after a heated debate about restricting access to the vaccine, which has been given to 1.4 billion people over the past three decades with an excellent safety record. Two members of the advisory committee demanded evidence of any harm from the vaccine, while others pointed out its benefits. Several advisers, who were hand-picked by Donald Trump's former health secretary Robert F Kennedy Jr, are longtime anti-vaccine advocates.
The delay in the vote is expected to give advisers more time to examine the wording before taking a decision. The move follows previous meetings where advisers recommended restricting access to Covid vaccines and measles, mumps, and rubella (MMR) vaccines, which has made it more difficult for families and providers to understand their options.
Experts warn that any change to the current hepatitis B vaccination schedule could have significant and far-reaching consequences for childhood health in the US. The leadership of the advisory committee was recently shaken up with the new chair, Kirk Milhoan, a pediatric cardiologist who has advocated against Covid vaccines and promoted the use of ivermectin.
The recommendation to vaccinate infants at birth has nearly eliminated transmission from birth parents and dramatically reduced cases of the illness in childhood. A study found that infant immunization is directly linked to a 99% decline in acute hepatitis B cases between 1990 and 2019.
Some members of the committee questioned the data presented, pointing out that studies have generally found the vaccine to be safe and well-tolerated. However, one member argued that some side effects like fatigue or weakness could be related to encephalitis.
Outside experts have also voiced concerns about the discussion, stating that the data presented are far from complete and that the 'CDC' presenters are not subject matter experts. The US population is diverse, and its healthcare system does not provide universal healthcare coverage, creating challenges to testing and follow-up vaccination for hepatitis B.
The delay in the vote has sparked fears that it could lead to more cases of liver cancer and deaths due to hepatitis B infection. Experts warn that delaying the shot from birth to two months would result in at least 1,400 infections, 300 cases of liver cancer, and 480 deaths every year β all preventable by vaccination.
The decision to delay the vote has been described as "speculation" by some members of the committee, while others have expressed concerns about the safety and effectiveness of the vaccine. The outcome of the revised vote is expected to be made public on Friday.
A contentious meeting between vaccine advisers for the US Centers for Disease Control and Prevention (CDC) has resulted in a delay to a vote on restricting hepatitis B vaccination for infants. The meeting, which took place earlier this week, turned confrontational at times before one member introduced a motion to delay the vote.
The decision comes after a heated debate about restricting access to the vaccine, which has been given to 1.4 billion people over the past three decades with an excellent safety record. Two members of the advisory committee demanded evidence of any harm from the vaccine, while others pointed out its benefits. Several advisers, who were hand-picked by Donald Trump's former health secretary Robert F Kennedy Jr, are longtime anti-vaccine advocates.
The delay in the vote is expected to give advisers more time to examine the wording before taking a decision. The move follows previous meetings where advisers recommended restricting access to Covid vaccines and measles, mumps, and rubella (MMR) vaccines, which has made it more difficult for families and providers to understand their options.
Experts warn that any change to the current hepatitis B vaccination schedule could have significant and far-reaching consequences for childhood health in the US. The leadership of the advisory committee was recently shaken up with the new chair, Kirk Milhoan, a pediatric cardiologist who has advocated against Covid vaccines and promoted the use of ivermectin.
The recommendation to vaccinate infants at birth has nearly eliminated transmission from birth parents and dramatically reduced cases of the illness in childhood. A study found that infant immunization is directly linked to a 99% decline in acute hepatitis B cases between 1990 and 2019.
Some members of the committee questioned the data presented, pointing out that studies have generally found the vaccine to be safe and well-tolerated. However, one member argued that some side effects like fatigue or weakness could be related to encephalitis.
Outside experts have also voiced concerns about the discussion, stating that the data presented are far from complete and that the 'CDC' presenters are not subject matter experts. The US population is diverse, and its healthcare system does not provide universal healthcare coverage, creating challenges to testing and follow-up vaccination for hepatitis B.
The delay in the vote has sparked fears that it could lead to more cases of liver cancer and deaths due to hepatitis B infection. Experts warn that delaying the shot from birth to two months would result in at least 1,400 infections, 300 cases of liver cancer, and 480 deaths every year β all preventable by vaccination.
The decision to delay the vote has been described as "speculation" by some members of the committee, while others have expressed concerns about the safety and effectiveness of the vaccine. The outcome of the revised vote is expected to be made public on Friday.